Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01614912 |
Recruitment Status
:
Completed
First Posted
: June 8, 2012
Last Update Posted
: July 1, 2015
|
Sponsor:
Sumitomo Dainippon Pharma Co., Ltd.
Information provided by (Responsible Party):
Sumitomo Dainippon Pharma Co., Ltd.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review
by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 2015 |
Study Completion Date : | No date given |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 | July 20, 2017 | December 15, 2017 |
2 | December 22, 2017 |